Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Supplement—October 2025
SUPPLEMENT ISSUE
Supplement
Long-Term Illness in Adults Hospitalized for Respiratory Syncytial Virus Disease, United States, February 2022–September 2023
Table 1
Characteristics of patients in a study of long-term illness in adults hospitalized for respiratory syncytial virus disease or COVID-19, United States, February 2022–September 2023*
| Category | Primary RSV cohort |
COVID-19, n = 118 | ||
|---|---|---|---|---|
| Overall, n = 146 | Age <60, n = 71 | Age >60, n = 75 | ||
| Demographics | ||||
| Age at admission, y (IQR) | 60.5 (49.0–70.0) | 49.0 (35.0–54.0) | 70.0 (65.0–75.0) | 64.5 (52.0–75.0) |
| Sex | ||||
| F | 88 (60.3) | 39 (54.9) | 49 (65.3) | 60 (50.9) |
| M | 58 (39.7) | 32 (45.1) | 26 (34.7) | 57 (48.3) |
| Race/ethnicity | ||||
| Non-Hispanic White | 68 (46.6) | 22 (31.0) | 46 (61.3) | 73 (61.9) |
| Non-Hispanic Black | 43 (29.5) | 26 (36.6) | 17 (22.7) | 27 (22.9) |
| Hispanic | 22 (15.1) | 15 (21.1) | 7 (9.3) | 11 (9.3) |
| Other | 8 (5.5) | 4 (5.6) | 4 (5.3) | 5 (4.2) |
| Unknown | 5 (3.4) | 4 (5.6) | 1 (1.3) | 2 (1.7) |
| Current/former smoker | 22 (15.1) | 12 (16.9) | 10 (13.3) | 21 (18.8) |
| Long-term care facility at admission† |
4 (2.7) |
1 (1.4) |
3 (4.0) |
5 (4.2) |
| Baseline characteristics at hospital admission | ||||
| Immunocompromised status | 44 (30.1) | 28 (39.4) | 16 (21.3) | 39 (33.1) |
| Cardiovascular disease | 99 (67.8) | 40 (56.3) | 59 (78.7) | 82 (69.5) |
| Neurologic disease | 9 (6.2) | 8 (11.3) | 1 (1.3) | 19 (16.1) |
| Pulmonary disease | 67 (45.9) | 25 (35.2) | 42 (56.0) | 38 (32.2) |
| Gastrointestinal disease | 6 (4.1) | 6 (8.5) | 0 (0.0) | 7 (5.9) |
| Endocrine disease | 53 (36.3) | 23 (32.4) | 30 (40.0) | 51 (43.2) |
| Renal disease | 40 (27.4) | 15 (21.1) | 25 (33.3) | 34 (28.8) |
| Hematologic disease | 24 (16.4) | 9 (12.7) | 15 (20.0) | 16 (13.6) |
| Autoimmune/inflammatory disease | 13 (8.9) | 8 (11.3) | 5 (6.7) | 9 (7.6) |
| Psychiatric disorders | 32 (21.9) | 18 (25.4) | 14 (18.7) | 32 (27.1) |
| No. organ systems with chronic disease (IQR)‡ | 2.0 (2.0–3.0) | 2.0 (1.0–3.0) | 2.0 (2.0–3.0) | 2.0 (1.0–3.0) |
| Baseline physical functioning limitations§ | 44 (30.1) | 18 (25.4) | 26 (34.7) | 50 (42.4) |
| COVID-19 vaccination, current season¶ |
50 (34.2) |
16 (22.5) |
34 (45.3) |
36 (30.5) |
| Characteristics of hospital course | ||||
| Intensive care unit admission | 36 (24.7) | 19 (26.8) | 17 (22.7) | 15 (12.7) |
| Severe hospital outcomes# | 53 (36.3) | 24 (33.8) | 29 (38.7) | 20 (17.0) |
| Hospital length of stay, d (IQR)** | 5.0 (3.0–9.0) | 4.0 (3.0–8.0) | 5.0 (3.0–10.0) | 4.0 (2.0–7.0) |
| Discharged to long-term care facility | 10 (6.9) | 4 (5.6) | 6 (8.0) | 15 (12.7) |
*Values are no. (%) except as indicated. Percentages for fields with missing values are computed based on the full column value. For those with RSV, variables missing data were current/former smoker (n = 12), long-term care facility at admission (n = 2), COVID-19 vaccination status (n = 2), and discharged to long-term care facility (n = 6). For those with COVID-19, variables missing data were sex (n = 1), current/former smoker (n = 6), long-term care facility at admission (n = 4), COVID-19 vaccination status (n = 4), and discharged to long-term care facility (n = 1). IQR, interquartile range; RSV, respiratory syncytial virus. †Including nursing homes, assisted living homes, and rehabilitation hospital or other subacute or chronic facility. ‡Organ systems affected by chronic disease: cardiovascular disease, neurologic disease, pulmonary disease, gastrointestinal disease, endocrine disease, kidney disease, hematologic disease, autoimmune disease, and immunocompromising conditions. §Baseline physical functioning limitations are defined as receiving home care help or unable to walk. ¶Defined for those hospitalized before September 1, 2022, as completion of a primary series plus 1 or 2 monovalent (original) boosters and for those hospitalized after September 1, 2022, as receipt of >1 bivalent vaccine doses #Defined as any of the following events during the acute illness hospitalization: deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, high-flow nasal cannula oxygen, noninvasive or invasive mechanical ventilation, new tracheostomy, new renal replacement therapy, use of vasopressors, or extracorporeal membrane oxygenation. **Those hospitalized >28 d had length of stay truncated at 28 d.
1A full list of collaborators in the IVY Network is provided in Appendix 1.